Cardiovascular & Hematological Disorders-Drug Targets

(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Garry X. Shen  
University of Manitoba
Winnipeg, MB
Canada

Back

Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients

Author(s): Natalia Antonio, Rosa Fernandes, Carlos Fontes Ribeiro, Luis A. Providencia.

Abstract:

Endothelial progenitor cells (EPCs) are a special type of stem cells, derived from bone marrow that can be mobilized to the peripheral circulation in response to many stimuli. EPCs play a crucial role in the vascular repair, as well as in neovascularization processes. Recent studies have shown that EPCs are impaired, both in number and function, in diabetic patients independently of other cardiovascular risk factors.

Accelerated atherosclerosis is probably the most devastating among diabetes complications and endothelial dysfunction might be the beginning of the atherosclerosis. The impairment of EPCs seems to significantly contribute to atherogenesis and atherosclerotic disease progression in diabetes.

Autologous EPCs therapy is a promising treatment option for vascular complications requiring therapeutic revascularization and vascular repair. Diabetic patients represent a population that may benefit from cell-based therapy; however, the dysfunction of their endogenous cells may limit the feasibility of this approach. In fact, EPCs isolated from these patients for autologous cell transplantation may retain their dysfunctional characteristics in vivo and as a consequence display a reduced capacity to improve therapeutic neovascularization.

In the present review, we summarize the most relevant mechanisms underlying EPC dysfunction in diabetes.

Keywords: Endothelial progenitor cells, diabetes, neovascularization, endothelial dysfunction, hyperglycemia, insulin resistance, Diabetes mellitus, DM, endothelial NO synthase, eNOS, eNOS uncoupling, EPCs a, hematopoietic stem cells, CD146, VEGFR2, KDR, vascular endothelial growth factor, VEGF, stromal-cell-derived fac-tor-1 (SDF-1), Phosphatidylinositol 3-Kinase (PI3k), serine-threonine kinase, (Akt)/eNOS, dyslipidemia, linoleic acids, Advanced glycation end products, AGEs, RAGEs, extracellular signal-regulated kinases, ERK, mitogen-activated protein kinase pathways

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 10
ISSUE: 3
Year: 2010
Page: [161 - 166]
Pages: 6
DOI: 10.2174/1871529X11006030161
Price: $58